Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

ABSTRACT:

Background

Metastasis-directed therapy (MDT) with stereotactic body radiotherapy (SBRT) is emerging as an effective therapeutic option for oligometastatic disease (OMD). However, a lack of phase III data, consensus guidelines, and toxicity concerns limit its widespread use. Randomized controlled trials (RCTs) routinely report hazard ratios (HRs) and medians that lack clear clinical and robust interpretation. Restricted-mean survival time (RMST) is the duration of time a patient is expected to survive over the follow-up period, providing a robust and interpretable alternative. We analyzed the efficacy of SBRT using RMST.

Methods

All registered RCTs of ablative radiotherapy in OMD in ClinicalTrials.gov through 2022 were identified. Data were reconstructed from Kaplan-Meier cur

SUBMITTER: Averbuch I 

PROVIDER: S-EPMC11183092 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature